On May 17, 1974, the U.S. Food and Drug Administration granted approval for ANDA 084088, covering VELTANE 4 mg oral tablets.
The product, submitted by Lannett, contains brompheniramine maleate as the active ingredient and is marketed as a prescription medication. VELTANE is an oral tablet (route: oral) with a dosage form of tablet, and it is not designated as a reference drug. The original submission (submission number 1) received an approved status (AP).
Actualités réglementaires16 sept. 2026•3 min de lecture
FDA Approves Lannett’s VELTANE 4 mg Oral Tablet (ANDA 084088)
The FDA has granted approval for Lannett’s generic VELTANE oral tablet containing 4 mg brompheniramine maleate (ANDA 084088).
Compilé par l'équipe Pharmacountry · Source : FDA.gov
Sujets :
Évaluations
(0)
(0)
(0)
(0)
(0)
Laissez votre note